Neurochemical basis of cannabis addiction

Neuroscience

Volumn 181, Issue , 2011, Pages 1-17

  Maldonado, R ^a   Berrendero, F ^a   Ozaita, A ^a   Robledo, P ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

CB1 receptor; Dopamine; Opioid; Reward; THC; Tolerance

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE; ADRENALIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; GLUTAMIC ACID; NORADRENALIN; OPIATE; OXYTOCIN; SEX HORMONE;

BEHAVIOR; CANNABIS ADDICTION; DOPAMINERGIC SYSTEM; DRUG TOLERANCE; HUMAN; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; REWARD; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN CHEMISTRY; CANNABINOIDS; DISEASE MODELS, ANIMAL; HUMANS; MARIJUANA ABUSE; RECEPTORS, CANNABINOID;

EID: 79953675661     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.02.035     Document Type: Review

References (213)

1. Abood M.E., Martin B.R. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992, 13:201-207.
2. Aceto M.D., Scates S.M., Lowe J.A., Martin B.P. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55,212-2. Eur J Pharmacol 2001, 416:75-81.
3. Adams M.D., Chait L.D., Earnhardt J.T. Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat. Br J Pharmacol 1976, 56:43-48.
4. Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., Weerapana E., Sadagopan N., Liimatta M., Smith S.E., Lazerwith S., Stiff C., Kamtekar S., Bhattacharya K., Zhang Y., Swaney S., Van Becelaere K., Stevens R.C., Cravatt B.F. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009, 16:411-420.
5. 2004 National Drug Strategy Household Survey: First Results 2005, AIHW, Australian Institute of Health and Welfare, AIHW cat. no. PHE 57, AIHW, Canberra, (Drug Statistics Series No. 13).
6. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002, 68:247-286.
7. The diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV) and proposed draft revisions (DSM-5) 2000, American Psychiatric Association.
8. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010, 160:467-479.
9. Baker D., Pryce G., Davies W.L., Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006, 27:1-4.
10. Ballon N., Leroy S., Roy C., Bourdel M.C., Charles-Nicolas A., Krebs M.O., Poirier M.F. AATn repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 2006, 6:126-130.
11. Balster R.L. Perception of drug effects. Comparative perception vol. I. Basics mechanims 1990, 127-154. John Wiley and Sons, New York. M.A. Berkley, W.C. Stebbins (Eds.).
12. Barrett R.L., Wiley J.L., Balster R.L., Martin B.R. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl) 1995, 118:419-424.
13. Beardsley P.M., Balster R.L., Harris L.S. Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 1986, 239:311-319.
14. Belin D., Mar A.C., Dalley J.W., Robbins T.W., Everitt B.J. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008, 320:1352-1355.
15. Benyamina A., Kebir O., Blecha L., Reynaud M., Krebs M.O. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol 2011, 16(1):1-6.
16. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008, 20(Suppl 1):1-9.
17. Braida D., Pozzi M., Cavallini R., Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001, 104:923-926.
18. Braida D., Pozzi M., Parolaro D., Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 2001, 413:227-234.
19. Braida D., Iosuè S., Pegorini S., Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 2004, 506:63-69.
20. Budney A.J., Hughes J.R. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006, 19:233-238.
21. Butovsky E., Juknat A., Elbaz J., Shabat-Simon M., Eilam R., Zangen A., Altstein M., Vogel Z. Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol Cell Neurosci 2006, 31:795-804.
22. Caillé S., Parsons L.H. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006, 31:804-813.
23. Castañé A., Robledo P., Matifas A., Kieffer B.L., Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 2003, 17:155-159.
24. Centonze D., Rossi S., De Chiara V., Prosperetti C., Battista N., Bernardi G., Mercuri N.B., Usiello A., Maccarrone M. Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. Eur J Neurosci 2007, 25:1631-1640.
25. Chaperon F., Soubrie P., Puech A.J., Thiebot M.H. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998, 135:324-332.
26. Cheer J.F., Marsden C.A., Kendall D.A., Mason R. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience 2000, 99:661-667.
27. Chen J., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L. Delta9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 1990, 102:156-162.
28. Cheng H.Y., Laviolette S.R., van der Kooy D., Penninger J.M. DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine. Eur J Neurosci 2004, 19:3033-3041.
29. Comings D.E., Muhleman D., Gade R., Johnson P., Verde R., Saucier G., MacMurray J. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 1997, 2:161-168.
30. Copeland J., Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry 2009, 21:96-103.
31. Copeland J., Swift W., Roffman R., Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001, 21:55-64.
32. Covault J., Gelernter J., Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry 2001, 6:501-502.
33. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
34. Cui S.S., Bowen R.C., Gu G.B., Hannesson D.K., Yu P.H., Zhang X. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J Neurosci 2001, 21:9867-9876.
35. De Chiara V., Errico F., Musella A., Rossi S., Mataluni G., Sacchetti L., Siracusano A., Castelli M., Cavasinni F., Bernardi G., Usiello A., Centonze D. Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 2010, 35:374-387.
36. De Vry J., Jentzch K.R., Kuhl E., Eckel G. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 2004, 15:1-12.
37. Deroche-Gamonet V., Belin D., Piazza P.V. Evidence for addiction-like behavior in the rat. Science 2004, 305:951-953.
38. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
39. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., Acquas E., Carboni E., Valentini V., Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004, 47(Suppl 1):227-241.
40. Di Marzo V., De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010, 17:1430-1449.
41. Diana M., Melis M., Muntoni A.L., Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci U S A 1998, 95:10269-10273.
42. Elsohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005, 78:539-548.
43. 2009 Annual report on the state of the drugs problem in Europe 2009, EMCDDA, European Monitoring Centre for Drugs and Drug Addiction.
44. Fadda P., Scherma M., Spano M.S., Salis P., Melis V., Fattore L., Fratta W. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006, 17:1629-1632.
45. Fattore L., Cossu G., Martellotta C.M., Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl) 2001, 156:410-416.
46. Fattore L., Cossu G., Spano M.S., Deiana S., Fadda P., Scherma M., Fratta W. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004, 16:147-158.
47. Fattore L., Fadda P., Spano M.S., Pistis M., Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008, 286(Suppl 1):S97-S107.
48. Fattore L., Spano M.S., Altea S., Angius F., Fadda P., Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol 2007, 152:795-804.
49. Fattore L., Spano M.S., Altea S., Fadda P., Fratta W. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol 2010, 160:724-735.
50. Fattore L., Vigano D., Fadda P., Rubino T., Fratta W., Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 2007, 25:2191-2200.
51. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005, 313:352-358.
52. Ferdinand R.F., Sondeijker F., van der Ende J., Selten J.P., Huizink A., Verhulst F.C. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005, 100:612-618.
53. Ferraro L., Tomasini M.C., Gessa G.L., Bebe B.W., Tanganelli S., Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 2001, 11:728-733.
54. Friedman A.S., Glassman K., Terras B.A. Violent behavior as related to use of marijuana and other drugs. J Addict Dis 2001, 20:49-72.
55. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.
56. García-Gutiérrez M.A., Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol 2010, 24:757-765.
57. García-Gutiérrez M.S., Pérez-Ortiz J.M., Gutiérrez-Adán A., Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010, 160:1773-1784.
58. Gardner E.L., Paredes W., Smith D., Donner A., Milling C., Cohen D., Morrison D. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology 1988, 96:142-144.
59. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 1996, 307:331-338.
60. Gessa G.L., Melis M., Muntoni A.L., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998, 341:39-44.
61. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002, 22:1146-1154.
62. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997, 17:5327-5333.
63. Good C.H., Lupica C.R. Afferent-specific AMPA receptor subunit composition and regulation of synaptic plasticity in midbrain dopamine neurons by abused drugs. J Neurosci 2010, 30:7900-7909.
64. Graham J.D., Lewis M.J., Li D.M. The effect of delta1-tetrahydrocannabinol on the release of 3H-(-)-noradrenaline from the isolated vas deferens of the rat. Br J Pharmacol 1974, 52:233-236.
65. Green B., Kavanagh D., Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003, 22:453-460.
66. Hall W. Dissecting the causal anatomy of the link between cannabis and other illicit drugs. Addiction 2006, 101:472-473.
67. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391.
68. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Cooper Z.D., Foltin R.W. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2010, 211:233-244.
69. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001, 98:3662-3665.
70. Hart C.L. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend 2005, 80:147-159.
71. Hartman C.A., Hopfer C.J., Haberstick B., Rhee S.H., Crowley T.J., Corley R.P., Hewitt J.K., Ehringer M.A. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend 2009, 12:127-136.
72. Heller D., Schneider U., Seifert J., Cimander K.F., Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users. Addict Biol 2001, 6:183-187.
73. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11-16.
74. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
75. Herman A.I., Kranzler H.R., Cubells J.F., Gelernter J., Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:499-503.
76. Higgins G.A., Fletcher P.J. Serotonin and drug reward: focus on 5-HT2C receptors. Eur J Pharmacol 2003, 480:151-162.
77. Hillard C.J., Bloom A.S. Delta 9-tetrahydrocannabinol-induced changes in beta-adrenergic receptor binding in mouse cerebral cortex. Brain Res 1982, 235:370-377.
78. Hillig K.W., Mahlberg P.G. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot 2004, 91:966-975.
79. Hojo M., Sudo Y., Ando Y., Minami K., Takada M., Matsubara T., Kanaide M., Taniyama K., Sumikawa K., Uezono Y. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008, 108:308-319.
80. Howlett A.C. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005, 168:53-79.
81. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002, 99:8400-8405.
82. Hutcheson D.M., Tzavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., Maldonado R. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 1998, 125:1567-1577.
83. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders?. CNS Neurosci Ther 2009, 15:65-75.
84. Ji S.P., Zhang Y., Van Cleemput J., Jiang W., Liao M., Li L., Wan Q., Backstrom J.R., Zhang X. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med 2006, 12:324-329.
85. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future national survey results on drug use, 1975-2006. Volume II: college students and adults ages 19-45 2007, (NIH Publication No. 07-6206).
86. Justinová Z, Ferré S, Redhi GH, Mascia P, Stroik J, Quarta D, Yasar S, Müller CE, Franco R, Goldberg SR (in press) Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addict Biol, in press.
87. Justinová Z., Munzar P., Panlilio L.V., Yasar S., Redhi G.H., Tanda G., Goldberg S.R. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 2008, 33:2870-2877.
88. Justinová Z., Tanda G., Munzar P., Goldberg S.R. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 2004, 173:186-194.
89. Justinová Z., Tanda G., Redhi G.H., Goldberg S.R. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 2003, 169:135-140.
90. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009, 89:309-380.
91. Karschner E.L., Darwin W.D., McMahon R.P., Liu F., Wright S., Goodwin R.S., Huestis M.A. Subjective and physiological effects after controlled sativex and oral THC administration. Clin Pharmacol Ther 2011, 89(3):400-407.
92. Kasanetz F., Deroche-Gamonet V., Berson N., Balado E., Lafourcade M., Manzoni O., Piazza P.V. Transition to addiction is associated with a persistent impairment in synaptic plasticity. Science 2010, 328:1709-1712.
93. Kaymakcalan S., Ayhan I.H., Tulunay F.C. Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 1977, 55:243-249.
94. Kinsey S.G., O'Neal S.T., Long J.Z., Cravatt B.F., Lichtman A.H. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 2011, 98:21-27.
95. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
96. Lecca D., Cacciapaglia F., Valentini V., Di Chiara G. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (Berl) 2006, 188:63-74.
97. Lepore M., Liu X., Savage V., Matalon D., Gardner E.L. Genetic differences in delta9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 1996, 58:PL3654-PL3725.
98. Lepore M., Vorel S.R., Lowinson J., Gardner E.L. Conditioned place preference induced by delta9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 1995, 56:2073-2080.
99. Li T., Liu X., Zhu Z.H., Zhao J., Hu X., Ball D.M., Sham P.C., Collier D.A. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000, 5:128-130.
100. Li J.X., McMahon L.R., Gerak L.R., Becker G.L., France C.P. Interactions between delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology (Berl) 2008, 199:199-208.
101. Lichtman A.H., Fisher J., Martin B.R. Precipitated cannabinoid withdrawal is reversed by delta(9)-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 2001, 69:181-188.
102. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 2001, 298:1007-1014.
103. Lichtman A.H., Martin B.R. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005, 168:691-717.
104. Lile J.A., Kelly T.H., Pinsky D.J., Hays L.R. Substitution profile of delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 2009, 203:241-250.
105. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavón F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
106. López-Moreno J.A., González-Cuevas G., Moreno G., Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 2008, 13:160-187.
107. Lynskey M.T., Coffey C., Degenhardt L., Carlin J.B., Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 2003, 98:685-692.
108. Macleod J., Oakes R., Copello A., Crome I., Egger M., Hickman M., Oppenkowski T., Stokes-Lampard H., Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
109. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 2002, 95:153-164.
110. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006, 29:225-232.
111. Mallet P.E., Beninger R.J. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta 9-tetrahydrocannabinol or anandamide. Psychopharmacology 1998, 140:11-19.
112. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004, 72:455-466. Marijuana Treatment Project Research Group.
113. Markou A., Weiss F., Gold L.H., Caine S.B., Schulteis G., Koob G.F. Animal models of drug craving. Psychopharmacol (Berl) 1993, 112:163-182.
114. Martellotta M.C., Cossu G., Fattore L., Gessa G.L., Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 1998, 85:327-330.
115. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993, 327:535-550.
116. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
117. McGregor I.S., Issackidis C., Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 1996, 53:657-664.
118. McLaren J., Swift W., Dillon P., Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008, 103:1100-1109.
119. Mechoulam R., Shani A., Edery H., Grunfeld Y. Chemical basis of hashish activity. Science 1970, 169:611-612.
120. Mehmedic Z., Chandra S., Slade D., Denham H., Foster S., Patel A.S., Ross S.A., Khan I.A., ElSohly M.A. Potency trends of δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010, 55:1209-1217.
121. Mendizabal V., Zimmer A., Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology 2006, 31:1957-1966.
122. Mokler D.J., Nelson B.D., Harris L.S., Rosecrans J.A. The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol. Life Sci 1986, 38:1581-1589.
123. Monory K., Blaudzun H., Massa F., Kaiser N., Lemberger T., Schütz G., Wotjak C.T., Lutz B., Marsicano G. Genetic dissection of behavioural and autonomic effects of delta(9)-tetrahydrocannabinol in mice. PLoS Biol 2007, 5:e269.
124. Monory K., Massa F., Egertová M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wölfel B., Dodt H.U., Zieglgänsberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
125. Moranta D., Esteban S., García-Sevilla J.A. Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:61-72.
126. Mucha R.F., Van der Kooy D., O'Shaughnessy M., Bucenieks P. Drug reinforcement studied by use of place conditioning in rat. Brain Res 1982, 243:91-105.
127. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
128. Naidu P.S., Kinsey S.G., Guo T.L., Cravatt B.F., Lichtman A.H. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 2010, 334:182-190.
129. Navarro M., Chowen J., Rocio A., Carrera M., del Arco I., Villanua M.A., Martin Y., Roberts A.J., Koob G.F., de Fonseca F.R. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998, 9:3397-3402.
130. Nomura D.K., Hudak C.S., Ward A.M., Burston J.J., Issa R.S., Fisher K.J., Abood M.E., Wiley J.L., Lichtman A.H., Casida J.E. Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett 2008, 18:5875-5878.
131. Okamoto Y., Wang J., Morishita J., Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers 2007, 4:1842-1857.
132. Olds J., Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 1954, 47:419-427.
133. Page M.E., Oropeza V.C., Van Bockstaele E.J. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 2008, 431:1-5.
134. Panlilio L.V., Justinová Z., Goldberg S.R. Animal models of cannabinoid reward. Br J Pharmacol 2010, 160:499-510.
135. Parker L.A., Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 1995, 109:71-78.
136. Pertwee R., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci 1995, 56:1949-1955.
137. Pertwee R.G. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005, 168:1-51.
138. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., Greasley P.J., Hansen H.S., Kunos G., Mackie K., Mechoulam R., Ross R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010, 62:588-631.
139. Pijlman F.T., Rigter S.M., Hoek J., Goldschmidt H.M., Niesink R.J. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005, 10:171-180.
140. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006, 12:21-38.
141. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001, 58:909-915.
142. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmacol 2002, 42:41S-47S.
143. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301:1020-1024.
144. Preuss U.W., Koller G., Zill P., Bondy B., Soyka M. Alcoholism-related phenotypes and genetic variants of the CB1 receptor. Eur Arch Psychiatry Clin Neurosci 2003, 253:275-280.
145. Puighermanal E., Marsicano G., Busquets-Garcia A., Lutz B., Maldonado R., Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 2009, 12:1152-1158.
146. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., Thompson M.R., Dawson B., Mallet P.E., Kashem M.A., Matsuda-Matsumoto H., Iwazaki T., McGregor I.S. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008, 33:1113-1126.
147. Racz I., Nadal X., Alferink J., Baños J.E., Rehnelt J., Martín M., Pintado B., Gutierrez-Adan A., Sanguino E., Manzanares J., Zimmer A., Maldonado R. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 2008, 28:12125-12135.
148. Rawls S.M., Gomez T., Raffa R.B. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav 2007, 86:499-504.
149. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244.
150. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Brelière J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998, 284:644-650.
151. Rios C., Gomes I., Devi L.A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006, 148:387-395.
152. Rodríguez de Fonseca F., Cebeira M., Ramos J.A., Martín M., Fernández-Ruiz J.J. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 1994, 54:159-170.
153. Rodríguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050-2054.
154. Rodríguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 2001, 21:823-833.
155. Rossi S., De Chiara V., Musella A., Kusayanagi H., Mataluni G., Bernardi G., Usiello A., Centonze D. Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 2008, 28:7284-7292.
156. Rowen D.W., Embrey J.P., Moore C.H., Welch S.P. Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. Pharmacol Biochem Behav 1998, 59:399-404.
157. Ryberg E., Larsson N., Sjögren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
158. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and mu opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001, 12:3689-3692.
159. Results from the 2008 National Survey on Drug Use and Health: National Findings 2008, SAMHSA, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, North Carolina.
160. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings 2010, SAMHSA, Substance Abuse and Mental Health Services Administration, (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856Findings), Rockville, MD.
161. Sanchis-Segura C., Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 2006, 11:2-38.
162. Sañudo-Peña M.C., Tsou K., Delay E.R., Hohman A.G., Force M., Walker J.M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 1997, 223:125-128.
163. Sañudo-Peña M.C., Force M., Tsou K., McLemore G., Roberts L., Walker J.M. Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome. Zhongguo Yao Li Xue Bao 1999, 20:1121-1124.
164. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., Nguyen P.T., Ramesh D., Booker L., Burston J.J., Thomas E.A., Selley D.E., Sim-Selley L.J., Liu Q.S., Lichtman A.H., Cravatt B.F. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010, 13:1113-1119.
165. Schmidt L.G., Samochowiec J., Finckh U., Fiszer-Piosik E., Horodnicki J., Wendel B., Rommelspacher H., Hoehe M.R. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 2002, 65:221-224.
166. Schoffelmeer A.N., Hogenboom F., Wardeh G., De Vries T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 2006, 51:773-781.
167. Smith P.B., Welch S.P., Martin B.R. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994, 268:1381-1387.
168. Solinas M., Goldberg S.R. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacol (Berl) 2005, 179:804-812.
169. Solinas M., Justinová Z., Goldberg S.R., Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006, 98:408-419.
170. Solinas M., Scherma M., Fattore L., Stroik J., Wertheim C., Tanda G., Fratta W., Goldberg S.R. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci 2007, 27:5615-5620.
171. Solinas M., Scherma M., Tanda G., Wertheim C.E., Fratta W., Goldberg S.R. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther 2007, 321:1127-1134.
172. Solinas M., Tanda G., Wertheim C.E., Goldberg S.R. Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of d(2)-induced formation of anandamide. Psychopharmacology (Berl) 2010, 209:191-202.
173. Solinas M., Zangen A., Thiriet N., Goldberg S.R. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur J Neurosci 2004, 19:3183-3192.
174. Soria G., Castañé A., Berrendero F., Ledent C., Parmentier M., Maldonado R., Valverde O. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci 2004, 20:2203-2213.
175. Spano M.S., Fattore L., Cossu G., Deiana S., Fadda P., Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 2004, 143:343-350.
176. Spiga S., Lintas A., Migliore M., Diana M. Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence. Addict Biol 2010, 15:266-276.
177. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
178. Stewart J.L., McMahon L.R. Rimonabant-induced delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 2010, 334:347-356.
179. Straiker A., Hu S.S., Long J.Z., Arnold A., Wager-Miller J., Cravatt B.F., Mackie K. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol 2009, 76:1220-1227.
180. Sugiura T., Kishimoto S., Oka S., Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006, 45:405-446.
181. Sugiura T., Kobayashi Y., Oka S., Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 2002, 66:173-192.
182. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
183. Szabo B., Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 2005, 168:327-365.
184. Tanda G., Loddo P., Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999, 376:23-26.
185. Tanda G., Munzar P., Goldberg S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000, 3:1073-1074.
186. Tanda G., Pontieri F.E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276:2048-2050.
187. Tanimura A., Yamazaki M., Hashimotodani Y., Uchigashima M., Kawata S., Abe M., Kita Y., Hashimoto K., Shimizu T., Watanabe M., Sakimura K., Kano M. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 2010, 65:320-327.
188. Thorat S.N., Bhargava H.N. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 1994, 260:5-13.
189. Tóth A., Blumberg P.M., Boczán J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 2009, 81:389-419.
190. Trigo J.M., Martin-García E., Berrendero F., Robledo P., Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend 2010, 108:183-194.
191. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 1980, 43:169-234.
192. Valjent E., Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 2000, 147:436-438.
193. Valverde O., Maldonado R., Valjent E., Zimmer A.M., Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 2000, 20:9284-9289.
194. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
195. Vanderschuren L.J., Everitt B.J. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 2004, 13:951-953.
196. Vaughan C.W., Christie M.J. Retrograde signalling by endocannabinoids. Handb Exp Pharmacol 2005, 168:367-383.
197. Vigano D., Rubino T., Vaccani A., Bianchessi S., Marmorato P., Castiglioni C., Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 2005, 182:527-536.
198. Viveros MP, Marco EM, López-Gallardo M, Garcia-Segura LM, Wagner EJ (in press) Framework for sex differences in adolescent neurobiology: a focus on cannabinoids. Neurosci Biobehav Rev.
199. Wade D.T., Makela P.M., House H., Bateman C., Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006, 12:639-645.
200. Wade D.T., Collin C., Scott C., Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010, 16:707-714.
201. Wagner F.A., Anthony J.C. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002, 26:479-488.
202. Ware M.A., St.Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010, 105:494-503.
203. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend 1997, 45:39-45.
204. Wiley J.L., Martin B.R. Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination. Pharmacol Biochem Behav 1999, 64:519-522.
205. Wilson A.R., Maher L., Morgan M.M. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 2008, 55:1219-1225.
206. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
207. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
208. Xi Z.X., Spiller K., Pak A.C., Gilbert J., Dillon C., Li X., et al. Cannabinoid CB1 receptor antagonists attenuate concaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 2007, 33:1735-1745.
209. Young A.M., Katz J.L., Woods J.H. Behavioral effects of levonantradol and nantradol in the rhesus monkey. J Clin Pharmacol 1981, 21:348S-360S.
210. Zangen A., Solinas M., Ikemoto S., Goldberg S.R., Wise R.A. Two brain sites for cannabinoid reward. J Neurosci 2006, 26:4901-4907.
211. Zhang P.W., Ishiguro H., Ohtsuki T., Hess J., Carillo F., Walther D., Onaivi E.S., Arinami T., Uhl G.R. Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004, 9:916-931.
212. Zimmer A., Valjent E., Koning M., Zimmer A.M., Clarke S., Robledo P., Chen C.C., Hahn H., Valverde O., Hill R.G., Kitchen I., Maldonado R. Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 2001, 21:9499-9505.
213. Zuo L., Kranzler H.R., Luo X., Covault J., Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry 2007, 62:616-626.